Parenteral Drugs (India) Q1, Q2, Q3, Q4, FY 2016-17, FY 2015-16 Standalone / Consolidated Results, Revenues, Net Profit, Tax, EPS, Live Chart …

Parenteral Drugs (India) Company Profile :

Parenteral Drugs (India) Limited is an India Based holding company involved in the business of manufacturing of allopathic pharmaceutical preparations.

Company also manufactures intravenous (IV) Fluids. It offers products in various categories, including IV fluids, oncology, anesthesia and exports. Its IV Fluids include Carbohydrated and Electrolytes, like Dextrose IP 25%, Ringer Lactate IP and Multiple Eletrolytes and Dextrose Injection IP Type I; Diuretics, like Mannitol 10%, 20%; Dialysis and Irrigation Solution, like Peritoneal Dialysis Solution with 1.7% Dextrose; Anti-infective and Anti-fungal, like Ciprofloxacin 200mg, and Others like Tamolgan (Paracetamol 1000mg).

Companys Oncology product mix includes 5 FU-PAR, BLEOPAR, BOTEPAR and BAZIPAR. Its Anesthesia product mix includes Sevoplan (Sevoflurane 100/250ml) and Isoplan (Isoflurane 100/250ml). Its exports products include CIPROFLOXACIN INJECTION USP WITH DEXTROSE and FLUCONAZOLE INJECTION USP.


Parenteral Drugs (India) Ltd ResultsBSE Code : 524689
NSE Symbol :  PDPL
ISIN No. : INE904D01019
Industry : Pharmaceuticals
Face Value : Rs. 10.00


If you are an investor who has shares of Parenteral Drugs (India) or you are an stock market analyst then i am sure you might for Quarterly Results of Parenteral Drugs (India).

In this article you will find Q1, Q2, Q3, Q4 and FY 2016-17 Results of Parenteral Drugs (India). That’s not all, you can compare those results with previous year i.e., FY 2015-16 Results of Parenteral Drugs (India).

Parenteral Drugs (India) Q1 Results 2016-17 :

Parenteral Drugs (India) will announce its Q1 FY 2016-17 Results in the month of July 2016. We will update the table below once the results are announced.

(Values in Cr.) Q1 Standalone Q1 Consolidated
Revenue
Other Income
Total Income
Expenditure
Interest
Depreciation
PBT
Tax  –
Net Profit  –
Equity  –
EPS  –

Parenteral Drugs (India) will announce its Q2 FY 2016-17 Results in the month of October 2016.

Parenteral Drugs (India) will announce its Q3 FY 2016-17 Results in the month of January 2017.

Parenteral Drugs (India) will announce its Q4 FY 2016-17 Results in the month of April 2017.

Parenteral Drugs (India) will announce its FY 2016-17 Results in the month of April 2017.

Note : We will update the results table above as and when results are announced. Visit again.

Parenteral Drugs (India) Previous Year’s Results (FY 2015-16) :

(Values in Cr.) Standalone Consolidated
Revenue 150.69
Other Income  –
Total Income  150.69
Expenditure  -196.72
Interest  -58.01
Depreciation  -17.06
PBT  -121.11
Tax  12.61
Net Profit  -108.49
Equity  29.82
EPS  -36.39

Note : If you like this information about Parenteral Drugs (India) Quarterly Results, then please share it with all your friends, relatives and other investors on Facebook, Twitter, WhatsApp, Email, etc.